Possible clustering and/or drug switching confounding obscures up to 56% reduction of symptom persistence by ivermectin. Data Summary for comment posted to JAMA re: Lopez-Medina et al.

This is a summary of our analysis of the dataset obtained from the study by López-Medina et al. (Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial, JAMA, 2021) supporting our comment posted to the JAMA web site: "Possible clustering and/or drug switching confounding obscures up to 56% reduction of symptom persistence by ivermectin."